XML 29 R11.htm IDEA: XBRL DOCUMENT

Balance Sheets-Additional Information

12 Months Ended

Jun. 30, 2017

Balance Sheets Additional Information [Abstract]

4. Balance Sheets—Additional Information

As of June 30	2017			2016
Accounts receivable, net
Trade accounts receivable		$	132,275		$	128,743
Allowance for doubtful accounts			(6,428)			(4,953)
		$	125,847		$	123,790

As of June 30	2017			2016			2015
Allowance for doubtful accounts
Balance at beginning of period		$	4,953		$	3,378		$	1,235
Provision for bad debts			1,412			1,774			2,587
Effect of changes in exchange rates			159			(132)			(218)
Bad debt write-offs (recovery)			(96)			(67)			(226)
Balance at end of period		$	6,428		$	4,953		$	3,378

As of June 30	2017			2016
Inventories
Raw materials		$	54,861		$	51,369
Work-in-process			12,402			8,074
Finished goods			93,970			108,248
		$	161,233		$	167,691

As of June 30	2017			2016
Property, plant and equipment, net
Land		$	9,584		$	9,612
Buildings and improvements			65,958			64,265
Machinery and equipment			212,589			196,480
			288,131			270,357
Accumulated depreciation			(160,780)			(143,034)
		$	127,351		$	127,323

Certain facilities in Israel are on leased land. The leases expire in 2023, 2035 and 2062.

Property, plant and equipment, net includes internal-use software costs, net of accumulated depreciation, of $3,558 and $5,180 at June 30, 2017 and 2016, respectively.

Machinery and equipment includes construction-in-progress of $2,690 and $5,595 at June 30, 2017 and 2016, respectively.

As of June 30	Weighted- Average Useful Life (Years)		2017			2016
Intangibles, net
Cost
Medicated feed additive product registrations		10		$	10,400		$	11,744
Amprolium international marketing rights		10			4,292			4,292
Customer relationships		13			10,616			10,606
Technology		13			67,907			66,960
Distribution agreements		4			3,222			3,275
Trade names, trademarks and other		5			2,740			2,740
In-process research and development					1,800			1,579
					100,977			101,196
Accumulated amortization
Medicated feed additive product registrations					(10,400)			(10,846)
Amprolium international marketing rights					(4,292)			(4,292)
Customer relationships					(6,995)			(6,303)
Technology					(18,776)			(13,877)
Distribution agreements					(3,222)			(3,275)
Trade names, trademarks and other					(2,690)			(2,508)
					(46,375)			(41,101)
				$	54,602		$	60,095

As of June 30	2017			2016
Goodwill roll-forward
Balance at beginning of period		$	21,121		$	12,613
Purchase price allocation correction			2,861			—
MVP acquisition			—			8,508
Balance at end of period		$	23,982		$	21,121

During the three months ended June 30, 2017, the Company determined goodwill and a liability for contingent consideration on acquisitions, initially recorded in the year ended June 30, 2015, were understated by $2,861. The Company corrected the error during the three months ended June 30, 2017, by adjusting goodwill, the liability and acquisition-related interest accrued subsequent to the acquisition date. We evaluated the effect of the error quantitatively and qualitatively, and concluded the error was not material to the current or any previously issued financial statements.

As of June 30	2017			2016
Other assets
Acquisition-related note receivable		$	5,000		$	5,000
Equity method investments			4,235			4,580
Insurance investments			5,097			4,833
Deferred financing fees			2,552			1,064
Deferred income taxes			23,269			28,019
Deposits			7,074			5,992
Other			6,570			6,977
		$	53,797		$	56,465

We evaluate our investments in equity method investees for impairment if circumstances indicate that the fair value of the investment may be impaired. The assets underlying a $3,719 equity investment are currently idled; we have concluded the investment is not currently impaired, based on expected future operating cash flows and/or disposal value.

As of June 30	2017			2016
Accrued expenses and other current liabilities
Employee related		$	26,553		$	21,712
Commissions and rebates			6,443			3,722
Insurance related			1,515			1,780
Professional fees			3,823			3,573
Income and other taxes			3,035			1,910
Contingent consideration on acquisitions			—			1,250
Other			11,283			11,756
		$	52,652		$	45,703

As of June 30	2017			2016
Other liabilities
U.S. pension plan		$	6,150		$	21,371
International retirement plans			5,257			5,600
Supplemental retirement benefits, deferred compensation and other			9,783			8,984
Long term and deferred income taxes			8,946			8,205
Contingent consideration on acquisitions			11,751			9,172
Other long term liabilities			7,666			7,981
		$	49,553		$	61,313

Contingent consideration on acquisitions includes $4,107 of accrued compensation related to the service of a key employee.

As of June 30	2017			2016
Accumulated other comprehensive income (loss)
Derivative instruments		$	2,686		$	2,655
Foreign currency translation adjustment			(43,556)			(41,904)
Unrecognized net pension gains (losses)			(18,059)			(30,977)
(Provision) benefit for income taxes on derivative instruments			(1,553)			(1,548)
(Provision) benefit for incomes taxes on long-term intercompany investments			8,166			8,166
(Provision) benefit for income taxes on pension gains (losses)			(3,121)			1,823
		$	(55,437)		$	(61,785)